 |
This is an archive page. The links are no longer being updated.
Testimony on Diabetes by Allen M. Spiegel, M.D., Director,
National Institute of Diabetes and Digestive and Kidney Diseases,
National Institutes of Health, U.S. Department of Health and
Human Services
Field Hearing before the Congressional Hispanic Caucus
at St. Phillip’s College in San Antonio, Texas
August 9, 2000
I appreciate the opportunity to testify at this Field Hearing
of the Congressional Hispanic Caucus. I am here today to convey
some of the excitement and hope we at the National Institutes
of Health (NIH) feel about our planned and ongoing research
to understand, treat and prevent diabetes. As the Director
of the NIH Institute with lead responsibility for diabetes
research, I know the enormous burden this disease places on
the Hispanic community and why it is of particular concern
to the people of South Texas. Diabetes is truly a devastating
disease that causes great personal and family suffering and
tremendous health care costs. It affects an estimated 16 million
Americans, who can be stricken by blindness, kidney failure,
amputations, heart disease, stroke, severe oral diseases,
nerve damage, and other destructive and painful complications
of the disease. Type 2 diabetes, the most prevalent form of
the disease, is marked by inadequate levels of insulin production,
as well as resistance to the action of the hormone insulin.
Type 2 diabetes is the form of the disease that strikes Mexican
Americans and other Hispanic groups the hardest. In early
1999, the Centers for Disease Control and Prevention (CDC)
reported that six percent of Hispanic adults in the United
States and Puerto Rico had been diagnosed with diabetes--twice
the rate of non-Hispanic Caucasians--while another six percent
were estimated to have undiagnosed diabetes. Diabetes is two-to-three
times more common in Mexican American adults than in non-Hispanic
Caucasians. Working together with all components of the diabetes
community, the NIH is committed to combating these grave health
disparities through strong and productive research programs
and outreach and education efforts.
The many Institutes and Centers of the NIH have a broad
research agenda to treat, prevent and cure diabetes and to
prevent the damage it causes to the eyes, kidneys, limbs,
mouth, and other parts of the body. Throughout the NIH, the
National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) leads and coordinates these efforts with a vigorous
research agenda aimed at conquering this devastating disease.
For example, our recently completed Strategic Plan to reduce
racial and ethnic health disparities includes major goals
and initiatives targeted to diabetes and its complications.
One of these new initiatives focuses on understanding the
metabolic, genetic, sociocultural and other factors that contribute
to the racial and ethnic differences in the cause and development
of complications resulting from type 2 diabetes. With new
knowledge gained from this initiative and other studies, we
hope to learn how to tailor therapies and prevention strategies
to specific populations, and thus increase their effectiveness.
In the upcoming year, the Institute will also launch initiatives
relating to the role of cellular damage and growth factors
in diabetic complications, prevention of heart disease in
diabetes, methods to prevent obesity in minority populations,
and genetic studies of diabetic kidney disease. In addition,
we plan to begin a new national kidney education program,
which will target messages to specific audiences, including
Hispanics. Diabetes patients now account for approximately
42 percent of the total number of cases of kidney failure
in the U.S., and we must find ways to put a stop to diabetic
kidney disease and the tragedy it causes.
Another area of new initiative will be studies aimed
at understanding the basis of and stemming the tide of type
2 diabetes in children. The recent rise in incidence of this
disease appears to be occurring largely in children from minority
groups--in parallel with a similar increase in obesity, which
we know is a major risk factor for type 2 diabetes. To address
this health problem, the NIDDK sought advice from a group
of scientific experts, including a pediatric endocrinologist
from San Antonio. Based on the recommendations from this meeting,
we subsequently issued a research solicitation, co-sponsored
by the National Institute of Child Health and Human Development.
We expect that our initiative will bring public and medical
attention, along with dedicated scientific talent, to help
solve this serious and disturbing children’s health issue.
These examples of new initiatives build upon the extensive
NIH portfolio of ongoing basic and clinical research on the
causes and natural history of diabetes. The hundreds of diabetes
research studies supported by the NIH are paving the way to
new insights and treatments to benefit diabetes patients and
their families. Advances in understanding the underlying causes
of diabetes are a critical first step in determining the factors
responsible for the higher rates of diabetes experienced by
Mexican Americans and other ethnic and racial minority populations.
Much basic research is therefore focused on understanding
the cascade of events in cell signaling that are required
for insulin to be properly secreted and for it to exert its
influence on blood glucose levels. The development of new
animal models and technologies for studying hormone action
at the molecular level is critical to these efforts.
Another important research area is genetics, where the
recently completed decoding of the human genome is accelerating
research to find and eliminate the causes of many diseases,
including diabetes. With new knowledge about the precise location
of genes, we can learn how genes function--how they interact
and what processes they control--to cause or prevent diseases
such as type 2 diabetes. In collaborative research, an international
consortium of scientists is pooling information in order to
map genes responsible for type 2 diabetes. Currently, the
consortium includes investigators representing 24 patient
groups from five countries. At locations in San Antonio--as
well as in Starr County, Texas, and in the San Luis Valley
in Colorado--the genetic linkage analysis includes a significant
number of Mexican American families.
Other investments in the discovery of genes and how they
function have led to the identification of at least six separate
genetic defects in rare forms of type 2 diabetes. Researchers
have recently shown that there are two interacting genes which
contribute to the susceptibility to type 2 diabetes in Mexican
Americans from Starr County, Texas. The identification of
the first of these susceptibility genes will soon be published--an
important advance. Collectively, these accomplishments are
helping us to solve the genetic puzzle of type 2 diabetes--an
extremely complex disease in which multiple genes are thought
to play a role. Each new clue to the dynamics of the disease
process gives us a tool for developing novel therapies and
prevention strategies to stop diabetes in its tracks.
In clinical research, key advances have shown how
the control of blood pressure, serum
cholesterol, and other lipids--as well as control of blood
glucose--is important in the comprehensive care of patients
with diabetes. Research has enabled the development of a second
generation of drugs for fighting type 2 diabetes, some with
different mechanisms of action that help physicians tailor
treatment to the needs of individual patients. With respect
to complications, NIH-supported clinical trials clearly demonstrated
the critical importance of maintaining close control of blood
sugar levels throughout the day. These landmark findings have
helped to spur the search for easier and more effective means
of blood glucose monitoring and control that patients can
use in the real world. Moreover, these findings helped pave
the way to the ongoing Diabetes Prevention Program (DPP)--a
large multicenter clinical trial of primary prevention strategies
for patients at high risk for developing type 2 diabetes.
This trial is being conducted at 27 centers across the United
States, including one at the University of Texas Health Science
Center here in San Antonio. The DPP has now completed patient
recruitment, with a total of over 3,800 participants--45 percent
of whom are from minority groups. We expect that findings
from this clinical trial will advance our understanding of
the factors that lead to the development of type 2 diabetes
and aid in pinpointing effective prevention strategies for
Mexican Americans and other high-risk groups.
Another clinical trial of great significance to type
2 diabetes is the Study of Health Outcomes of Weight-loss
(SHOW), which is slated to begin recruitment next Spring.
This large, multicenter trial plans to enroll approximately
6,000 patients at 16 locations throughout the United States,
including the University of Texas Health Science Center in
San Antonio. The SHOW trial will include participants from
a range of Hispanic populations, including over 350 Mexican
Americans.
Complementing the many basic and clinical diabetes research
programs of the NIH are critically important diabetes education
and information programs--built on science-based messages.
The National Diabetes Education Program (NDEP) is a joint
undertaking of the NIH and the CDC, with over 200 public and
private partners--including several Hispanic organizations.
In accordance with its objectives of improving the treatment
and outcomes for people with diabetes in order to reduce illness
and death, the NDEP has a national media campaign especially
targeted to the Hispanic and Latino community, entitled, "Thunder
and Lightening." Launched in 1998, this campaign includes
television, radio and print public service ads that were released
to over 1,000 Spanish-language media outlets nationwide and
in Puerto Rico. October 1999 marked the release of a second
edition of the campaign, which includes a new series of television,
radio and print ads. The NIH and the CDC developed these campaigns
with extensive direction and guidance from a participating
Hispanic/Latino Work Group, comprised of representatives from
several Hispanic health organizations. An upcoming campaign
will be the development of nutrition education messages and
materials, to be launched this Fall, targeting Hispanics and
Latinos with type 2 diabetes and their families. The goal
is to encourage individuals to control their diabetes by making
healthy food choices.
To bring the message of the National Diabetes Education
Program to the community, we call upon key organizations--such
as the National Council of LaRaza, COSMO, and the National
Hispanic Council on Aging--to help distribute culturally appropriate
diabetes education messages through established community
channels. Complementing these education campaigns is the National
Diabetes Information Clearinghouse, which provides many fact
sheets and pamphlets about diabetes and its management in
easy-to-read formats in English and Spanish.
Today, I have shared with you just a few examples of
NIH programs aimed at conquering type 2 diabetes and halting
its heavy burden for the Mexican American community and other
Hispanic groups. I believe that our national research and
educational programs--in partnership with the private sector,
communities, and voluntary and professional organizations--hold
the key to eliminating diabetes. We have many important and
promising initiatives under way, to which NIH supported researchers
are devoting amazing talents and energy. There are many examples
of impressive progress, along with ongoing studies that offer
great hope. Nevertheless, we recognize that much more work
must be done to combat and ultimately conquer diabetes. I
am very grateful to have the opportunity to present this testimony
today and am pleased to answer any questions you may have.
|